NAVBQ — Navidea Biopharmaceuticals Balance Sheet
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.01m
- -$2.31m
- $0.07m
Annual balance sheet for Navidea Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 4.28 | 1.05 | 2.67 | 4.23 | 2 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.021 | 0.901 | 2.99 | 0.093 | 0.001 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 5.6 | 2.92 | 6.53 | 5.38 | 3.2 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.162 | 0.312 | 0.382 | 0.249 | 0.156 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 7.02 | 4.15 | 7.76 | 6.64 | 4.37 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.38 | 3.82 | 4.72 | 5.3 | 9.94 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 5.28 | 5.76 | 6.44 | 6.75 | 12.8 |
| Redeemable Preferred Stock | |||||
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 1.74 | -1.61 | 1.32 | -0.107 | -8.44 |
| Total Liabilities & Shareholders' Equity | 7.02 | 4.15 | 7.76 | 6.64 | 4.37 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |